Coiled Therapeutics begins trading on AIM after £8.5m raise

Coiled Therapeutics raised £8.5m by issuing 85m new shares at 10p and commenced trading on AIM, coinciding with acquisition of an exclusive worldwide license to AO-252. Early Phase I data reported tumor reductions up to 33% (endometrial) and 29% (ovarian) at sub-therapeutic exposures; the company plans to expand AO-252 Phase I into prostate and ovarian cancers with data readouts expected by Q4 2026. The funding is intended to support clinical development milestones in 2026–2027, and the company is also evaluating a STAT-6 siRNA programme for Phase I immunology trials.

Analysis

An early-stage, brain-penetrant small-molecule showing signal at sub‑therapeutic exposures is a classic asymmetric biotech bet: low current valuation with binary clinical-readout upside but high dilution and execution risk. The mechanistic profile (brain penetration + targeted inhibition) widens potential indications beyond a single tumor type, creating optionality that can compress time to partnering interest from specialty pharma—expect M&A chatter to appear well before randomized data if dose‑dependent responses persist.

Second-order beneficiaries include niche CROs, translational-biomarker providers and companies that commercialize companion-diagnostic platforms; these firms typically see near-term revenue catch-up from small expanded cohorts and biomarker-driven enrollment. Conversely, small-cap peers without biomarker-enabled strategies may undergo negative re-rating as capital reflows toward companies demonstrating early, target-validated activity.

Key risks are classic Phase I failure modes: non‑reproducible response, narrow therapeutic index on dose escalation, and cash runway shortfalls prompting dilutive financings ahead of pivotal inflection points. Near-term catalysts that would materially re‑rate the story are clear dose‑response, biomarker correlations, and independent safety signals; any sign of plateauing response or serious adverse events would rapidly unwind sentiment.

From a portfolio construction perspective, treat exposure as high-volatility alpha: small, event-driven allocation with active hedging and strict capital preservation controls. Time horizons should be event-driven (weeks–months) for headline readouts and 12–24 months for partnership or raise scenarios; monitor enrollment velocity and CRO bookings as early diagnostic indicators of program health.

Key Decisions for Investors

• Speculative long COIL (AIM:COIL) — 0.25% NAV position size, horizon 3–9 months to next cohort readouts. Use a hard 30% stop or buy 6–9 month OTM protective puts if liquid; reward profile: binary upside 3x–10x on positive cohort signal versus limited cash-loss if fully diluted.
• Hedge pair: Long COIL (AIM:COIL) vs Short XBI (SPDR S&P Biotech ETF) equal-dollar — timeframe 3–6 months to isolate idiosyncratic clinical outcome risk. Expect payoff if asset-specific biology is confirmed while sector selling reduces gross exposure; initial target: 20–40% relative outperformance before trimming.
• Tactical long in CRO/clinical-services (e.g., ICLR) — 0.5–1% NAV, horizon 6–18 months. Rationale: increased early-stage activity and expansion cohorts lift enrollments and services revenue; downside: clinical spending pullback if sentiment collapses, set 15% stop-loss.